Navigation Links
URMC heart research expands to Asia with launch of new device trial
Date:8/9/2013

Cardiologists at the University of Rochester Medical Center are launching a new study in an effort to improve the treatment of a very common form of heart disease in the Asian population.

Called MADIT-Asia, the study is the first to test cardiac resynchronization therapy a device that improves the mechanical pumping action of the heart in Asian patients with non-coronary heart disease. Though the majority of heart disease in the United States is caused by cholesterol-clogged arteries that restrict blood flow from the coronary arteries to the heart, the opposite is true in Asia, where there's a much higher proportion of heart disease that's caused by virus or, in many cases, unknown factors.

"This study is important because there has been almost no research related to the treatment of non-ischemic or non-coronary heart disease in this population; most trials have taken place in the United States and Europe," noted principal investigator Arthur J. Moss, M.D., cardiology professor at the University of Rochester Medical Center and a leading expert on cardiac device therapy.

Moss says the study is also the first to test an innovative approach using two leads or wires instead of the usual three to send electrical impulses from the cardiac resynchronization therapy device to the heart to help it beat in a more balanced way. The leads, which are positioned in specific spots in the heart at the time of device implantation, can get infected, fracture, or even pierce a vein if not positioned properly by a skilled clinician.

"Preliminary evidence suggests that a two-lead system is just as effective, if not more effective, than a three-lead system," said Moss. "Fewer leads would be better and would most likely translate into fewer complications for patients."

The trial, sponsored by Boston Scientific, will enroll 180 patients from China, Hong Kong (part of China, but medically it operates differently), Japan, South Korea, Taiwan, Singapore, Thailand, Malaysia and India. Half of the patients will receive cardiac resynchronization therapy using two leads plus standard medical management and the other half will be managed medically. The team, which is ready to enroll the first patients in the trial, will use echocardiogram readings to determine improvement in heart function in each group.

This is the latest trial in the series of MADIT (Multicenter Automatic Defibrillator Implantation Trial) studies, which Moss has led since their inception in the early 1990's. His major findings include: Preventive therapy with an implantable cardioverter defibrillator or ICD significantly reduces the risk of death in heart attack survivors; cardiac resynchronization therapy plus defibrillator (CRT-D therapy) prevents the progression of heart failure in patients living with mild forms of the disease; and a simple change in the way physicians program CRT-D devices dramatically reduces inappropriate therapies potentially painful shocks delivered for rhythms that aren't life threatening and significantly increases survival in people with heart disease.

Moss holds no stock in any device company, has never been a member of any corporate speakers bureau and since December 1, 2008, has chosen not to accept honoraria from Boston Scientific for any professional activity.


'/>"/>

Contact: Emily Boynton
emily_boynton@urmc.rochester.edu
585-273-1757
University of Rochester Medical Center
Source:Eurekalert

Related medicine news :

1. Heartburn No More System Review Exposes New Efficient Heartburn Treatment
2. Study: Heart pump with behind-the-ear power connector
3. Santa Rosa Boot Camp Celebrates Successful 1,000lb Meltdown Challenge by Donating All Proceeds to the American Heart Association
4. UC Davis "Lab on a Chip" Measures Heart Disease Risk
5. MedHelp to Host Online Chat on How Cancer Treatment Can Affect Heart Health
6. AED.com Encourages Kidd Kraddick Fans to Examine Their Heart Health
7. Beaumont Health System Launches Research Trial of Bioresorbable Heart Scaffold
8. Researchers identify genetic mutation linked to congenital heart disease
9. Beaumont Health System launches research trial of bioresorbable heart scaffold
10. A Checklist for Heart Attack Prevention, from the July 2013 Harvard Men's Health Watch
11. Increased Risk of Heart Disease Associated With Long-Term Obesity Article Published by Health News Wires
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/6/2016)... ... February 06, 2016 , ... With the FCPX LUT: Summer ... to their footage. A LUT is a Lookup Table that contains a mathematical formula ... indicated by the table. By manipulating each pixel, LUT's can change each color range ...
(Date:2/6/2016)... , ... February 06, 2016 , ... ... of eating disorder treatment helps to reduce the frequency and level of relapse. ... Recovery Phase: Re-Establishing Healthy Identity and Purpose,” will explore the critical tasks of ...
(Date:2/5/2016)... ... , ... Love is in the air at King Kullen! The local grocer ... This staple for Valentine’s Day is a must-have, and can be picked up with ... only are long-stem roses available, but also other flower bouquets, elegantly wrapped and ready ...
(Date:2/5/2016)... ... February 05, 2016 , ... Today, the Whole-Food Warrior ... that the much-anticipated feature with author Jahnavi Foster, specialist in healthy vegetarian cuisine, will ... , Each week, on his weekly Whole-Food Warrior TV show, Frank Davis highlights Whole-Food ...
(Date:2/5/2016)... ... 05, 2016 , ... The event is being held on April 7, 2016 ... Minn. Triumph Over Parkinson’s will fund nearly $100,000 for research for the care and ... Parkinson’s disease and is the architect of this informative event to raise awareness and ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... 2016  The Senior Care Pharmacy Coalition (SCPC) ... Chairman Jason Chaffetz (R-UT) and Ranking ... hearing , "Developments in the Prescription Drug Market," ... questions about abusive pharmacy benefit manager (PBM) pricing ... Ranking Member Elijah Cummings (D-MD) are diligent, serious ...
(Date:2/4/2016)... , Feb. 4, 2016  Montoya Love is recognized ... the field of Pharmaceuticals. Montoya is the Regulatory Systems ... Manufacturing and selling ... Becton Dickinson provides healthcare institutions, clinical laboratories and ... fifty countries across the globe. ...
(Date:2/4/2016)... -- Mettler-Toledo International Inc. (NYSE: MTD ) today ... the highlights: , Sales in local currency ... year.  Reported sales decreased 3% as currency reduced sales ... earnings per diluted share as reported (EPS) were $4.44, ... EPS was $4.65, an increase of 10% over the ...
Breaking Medicine Technology: